Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 7/20 | 1.00 |
| ▸ | DRD2 | P14416 | 7/20 | 1.00 |
| ▸ | HRH1 | P35367 | 7/20 | 1.00 |
| ▸ | HTR1A | P08908 | 6/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 6/20 | 1.00 |
| ▸ | DRD1 | P21728 | 6/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 6/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 5/20 | 1.00 |
| ▸ | HTR2A | P28223 | 5/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 4/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 4/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 4/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 4/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 4/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thioproperazine SCHEMBL29394708 | 1.00 | DRD3 (1.00) | DRD3DRD2HRH1HTR1AADRA2A | |
| Thioproperazine SCHEMBL29372322 | 1.00 | DRD3 (1.00) | DRD3DRD2HRH1HTR1AADRA2A | |
| Thioproperazine SCHEMBL2386850 | 0.96 | CYP3A4 (1.00) | DRD3DRD2HRH1HTR1AADRA2A | |
| Thioproperazine SCHEMBL3027811 | 0.96 | CYP3A4 (1.00) | DRD3DRD2HRH1HTR1AADRA2A | |
| Thioproperazine SCHEMBL29888916 | 0.96 | CYP3A4 (1.00) | DRD3DRD2HRH1HTR1AADRA2A | |
| Thioproperazine SCHEMBL11047989 | 0.93 | DRD3 (0.86) | DRD3DRD2HRH1HTR1AADRA2A | |
| Thioproperazine SCHEMBL11047988 | 0.93 | DRD3 (0.86) | DRD3DRD2HRH1HTR1AADRA2A | |
| SCHEMBL6946497 | 0.92 | DRD3 (0.85) | DRD3DRD2HRH1HTR1AADRA2A | |
| SCHEMBL10136896 | 0.92 | DRD2 (0.85) | DRD3DRD2HRH1HTR1AADRA2A | |
| SCHEMBL10136877 | 0.92 | DRD3 (0.85) | DRD3DRD2HRH1HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3334 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527754-B2 | Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions | TUFTS MEDICAL CENTER, INC. (US) | 2026-01-20 | — | — | US | claimed |
| EP-4618973-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | Sumitomo Pharma America, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS LLC | 2025-06-05 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025101418-A1 | TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS IN PATIENTS WITH PROMINENT ANHEDONIA USING IRDABISANT AS A MONOTHERAPY OR IN COMBINATION WITH AN ANTIPSYCHOTIC AGENT | ALTO NEUROSCIENCE, INC. (US) | 2025-05-15 | — | — | WO | claimed |
| US-20250144092-A1 | TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS IN PATIENTS WITH PROMINENT ANHEDONIA USING IRDABISANT AS A MONOTHERAPY OR IN COMBINATION WITH AN ANTIPSYCHOTIC AGENT | ALTO NEUROSCIENCE, INC. | 2025-05-08 | — | — | US | claimed |
| US-20240261236-A1 | METHODS OF USING NMDA RECEPTOR ANTAGONISTS | SEELOS THERAPEUTICS, INC. | 2024-08-08 | — | — | US | claimed |
| WO-2024107681-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2024028611-A1 | OXADIAZOLE COMPOUNDS FOR USE IN THE TREATMENT OF OBSESSIVE COMPULSIVE DISORDER | SIRGARTAN HOLDINGS LTD (GB) | 2024-02-08 | — | — | WO | claimed |
| US-20240000810-A1 | USE OF CANNABINOIDS IN THE TREATMENT OF TOURETTE SYNDROME AND TIC DISORDERS | Orcosa Inc. (US) | 2024-01-04 | — | — | US | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-1005651-A1 | METHODS OF IDENTIFYING BIOLOGICAL AGENT COMPOSITIONS | SUPRATEK PHARMA, INC. (CA) | 2000-06-07 | — | — | EP | claimed |
| CN-1251526-A | New therapeutic combinations of mirtazapine and antipsychotic agents, for treatment of prophylaxis of psychotic disorders | AKZO NOBEL NV (NL) | 2000-04-26 | — | — | CN | claimed |
| EP-0969845-A1 | NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE AND ANTIPSYCHOTIC AGENTS, FOR THE TREATMENT OR PROPHYLAXIS OF PSYCHOTIC DISORDERS | Akzo Nobel N.V. (NL) | 2000-01-12 | — | — | EP | claimed |
| WO-1999008112-A1 | METHODS OF IDENTIFYING BIOLOGICAL AGENT COMPOSITIONS | SUPRATEK PHARMA INC. (CA) | 1999-02-18 | — | — | WO | claimed |
| WO-1998043646-A1 | NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE AND ANTIPSYCHOTIC AGENTS, FOR THE TREATMENT OR PROPHYLAXIS OF PSYCHOTIC DISORDERS | AKZO NOBEL N.V. (NL) | 1998-10-08 | — | — | WO | claimed |
| WO-1996001631-A1 | NOVEL COMBINATION PRODUCT COMPRISING CAPRIPRAMINE AND A NEUROLEPTIC | PIERRE FABRE MEDICAMENT (FR) | 1996-01-25 | — | — | WO | claimed |
| EP-0180364-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PHENOTHIAZINES | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1990-03-07 | — | — | EP | claimed |
| EP-0180364-A2 | Pharmaceutical compositions containing phenothiazines | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1986-05-07 | — | — | EP | claimed |
| US-4175119-A | Composition and method to prevent accidental and intentional overdosage with psychoactive drugs | PORTER GARRY L | 1979-11-20 | — | — | US | claimed |